In 2012, employers looked most for professionals in IT or software services, FMCG industries and BPO or ITES, followed by real estate and pharmaceuticals or life sciences to fill mid or senior positions.
India Inc is expected to offer average salary increments of 11.3 per cent this fiscal and those working in sectors like pharmaceuticals, health care and life sciences are expected to get a raise of 13.1 per cent.
As India gets ready to roll out one of the largest vaccine programmes, billionaire Mukesh Ambani on Tuesday said his group is working with authorities to provide technology tools and backbone for mass inoculation against COVID-19. Ambani's telecom venture Jio was rolled out four years back, offering free voice calling and dirt-cheap data. Today, Jio is India's largest telecom operator with over 400 million users, each connected to the internet. At a Facebook event, Ambani said the government's digital push kept the country running even during the pandemic and is now helping in the rollout of one of the largest vaccination programmes.
The patent application for 'System and method for wearable electronic devices', filed in 2007, mentions various wearable models including a shoe that can communicate data to the user, electronic communication devices attached to clothes, wireless ear pieces and ankle bracelets that can transmit updated information from the body to the user. The drawings the company submitted to the patent office also show the design of a shoe that can be a wearable electronic device.
Former President A P J Abdul Kalam felicitated the six winners.
The quarter also saw exits worth $1.9 billion across 37 deals, 59 per cent higher YoY. This was driven by one of India's largest PE-backed IPO exit, the $1-billion partial exit by Carlyle in the SBI Cards IPO.
Wipro's clients currently include over 100 US payers, healthcare providers, and public health agencies.
A visiting trade delegation from Toronto, which met with local entrepreneurs and investors here on Tuesday, said it would focus on attracting investments into information and communication technology, life sciences and renewable energy sectors.
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
The Infosys Science Foundation on Thursday awarded winners of Infosys Prize 2010 recognising their outstanding achievements in scientific research.
There has been speculation that Infosys is at an advanced stage of talks to buy a US firm operating in the public services and healthcare space.
Shanghvi needs to deploy this excess cash.
From announcing a lockdown and extending its tenure, setting up the country's first two exclusive Covid-19 hospitals, creating a hotspot zone, providing doorstep medical service and making masks compulsory, the state is doing all it can to dwarf the virus.
Eminent Indian-origin academician Srikant Datar has been named as Dean of Harvard Business School, succeeding Nitin Nohria and becoming the second consecutive dean hailing from India to lead the prestigious 112-year-old institution. Datar, an alumnus of University of Bombay and Indian Institute of Management, Ahmedabad, is the Arthur Lowes Dickinson Professor of Business Administration and the senior associate dean for University Affairs at Harvard Business School (HBS). He will assume charge as the school's next dean on January 1, president Larry Bacow said.
The Infosys Science Foundation on Monday announced the winners of the Infosys Prize 2010 recognizing outstanding contributions to scientific research that have impacted India.
Daiichi Sankyo, Japan's third-largest drug maker, has transferred six of its early drug discovery programmes in inflammatory and infectious diseases from its Japanese research & development (R&D) facilities to India.
The health ministry on Saturday recommended the use of antiviral drug remdesivir in moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients.
Over time, as more mutations occur, the vaccine may need to be altered.
India will prefer to voluntarily surrender the grant it receives from United Kingdom if the British government decided on cutting it, Finance Minister Pranab Mukherjee told Rajya Sabha on Tuesday.
'It is safe to consume cooked non-vegetarian food.'
Utah Youth Village presented its highest honour, the 2010 Helping Hand award, to nationally recognised life sciences innovator Dr Dinesh Patel for his 'extraordinary love and support for Utah's most vulnerable children.'
Indian companies are likely to shell out an average salary increment of 10.3 per cent in the current fiscal with employees in pharma, health care and life sciences projected to get 12.4 per cent raise, says a survey.
According to SOP, those testing positive will be isolated in a separate unit of an institutional facility.
Titan accounted for 59.6 per cent of his disclosed portfolio at Rs 8,355 crore. This is more than 10 times the next biggest holding, Federal Bank, at Rs 619 crore.
Major drug discovery outsourcing deals have almost dried up in the past 18 months for almost all prominent players in the area
Professor Shankar Balasubramanian has been awarded the prize, worth 10,000 pounds, for his work on Solexa sequencing, the high speed genome sequencing technology that means it is now possible to sequence a human genome for less than $10,000.
Jhunjhunwala increases stake in DHFL, luggage maker VIP Industries and pharma major Lupin but is cautious on auto holding. At the end of the March quarter, Jhunjhunwala held positions in 29 firms.
Plans to set up an integrated pharma firm in a phased manner.
Harvard-educated Piramal is also in the boards of several companies, including Piramal Life Sciences, SBI Capital Markets Ltd and Prudential ICICI Management.
He did not believe in any fiscal puritanism. In 2012, when it was almost certain that the government will breach the 2012-13 fiscal deficit target, he wrote that in abnormal times, abnormal measures are required to get back to normalcy.
Indian drug companies, which have introduced copies of biotechnology drugs in the country, are bullish over the marketing prospects of 'biogenerics' after patents expire in developed markets. Experts say Indian companies may not repeat the success they achieved in selling generic medicines in biogenerics. The cost of clinical trials and the absence of substitutability will ensure that only those with deep pockets to launch such products globally will succeed, they feel.
"I believe that we have the potential of dominating the Asian economy," he said.
PLSL's lead molecule under development for cancer treatment has completed two Phase-I studies.
The Department of Management Sciences, University of Pune's two year full time MBA (Biotechnology) Degree programme.
Companies are back with their hiring plans as the economy shows signs of recovery with a boost in domestic demand.
Indian venture capitalists and private equities are expected to invest over $8.5 billion (about Rs 42,000 crore) in the next five years in sectors like biotechnology, life sciences, film production and education, an Assocham-Deloitte study said.
The latest one being Ken Toombs, global head of consulting at the Bengaluru-based entity.
Record equity divestment by the Reliance Group in its telecom and retail businesses garnering around $23 billion revved up the deal street in 2020, which otherwise would have gone down as one of the dullest on record, and dealmakers are seeing sunnier days in 2021 given the large scope for consolidation in a slew of sectors ravaged by the pandemic. With Jio Platforms alone garnering over $16 billion (Rs 1,18,318 crore) by selling 25.24 per cent stake and Reliance Retail notching up $6.4 billion (Rs 47,265 crore) by divesting around 9 per cent shareholding, the deal street signed off with $85 billion in the deal kitty across 1,270 transactions. This is higher by about 10 per cent over 2019. What is significant is that over a third of the total deal value came from Reliance transactions, say investment bankers.
Private equity firms invested about USD 3.7 billion across 133 deals during the first quarter of 2018 as compared to USD 7.3 billion by way of 200 transactions a year ago.
Applications are invited for PG Diploma Course in Stem Cell Technology & Tissue Engineering (Full Time.
